Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.

@article{Greenstone1998ChimericPV,
  title={Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.},
  author={Heather L. Greenstone and John Dirk Nieland and Karin E. de Visser and Marloes de Bruijn and Reinhard Kirnbauer and Richard B S Roden and Douglas R Lowy and Wijbe Martin Kast and John T. Schiller},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={1998},
  volume={95 4},
  pages={1800-5}
}
Papillomavirus-like particles (VLPs) are a promising prophylactic vaccine candidate to prevent human papillomavirus (HPV) infections and associated epithelial neoplasia. However, they are unlikely to have therapeutic effects because the virion capsid proteins are not detected in the proliferating cells of the infected epithelia or in cervical carcinomas. To increase the number of viral antigen targets for cell-mediated immune responses in a VLP-based vaccine, we have generated stable chimeric… CONTINUE READING